Ampio Pharmaceuticals Stock News

Ampio Pharmaceuticals Inc (NYSE: AMPE) received written responses from the FDA pursuant to a Type C meeting request regarding the AP-013 Phase 3 trial results.  In March, Ampio announced data from t

AMPE, ANIK, and FAT have been added to the Zacks Rank #5 (Strong Sell) List on April 7, 2022.

AMPE, ANIK, and FAT have been added to the Zacks Rank #5 (Strong Sell) List on April 7, 2022.

AKYA, AMPE, and BITF have been added to the Zacks Rank #5 (Strong Sell) List on April 1, 2022.

AKYA, AMPE, and BITF have been added to the Zacks Rank #5 (Strong Sell) List on April 1, 2022.

Ampio Pharmaceuticals, Inc. (AMPE) CEO Michael Martino on Q4 2021 Results - Earnings Call Transcript

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Pfizer Announces Positive Results From Second Late-Stage Study Of Ulcerative Colitis Drug Pfizer, Inc.

Upgrades For iRobot Corp (NASDAQ:IRBT), Northland Capital Markets upgraded the previous rating of Market Perform to Outperform. In the fourth quarter, iRobot showed an EPS of $1.05, compared to $0.84

Ampio Pharmaceuticals Inc (AMEX:AMPE) shares are trading significantly higher Thursday following bullish analyst coverage. Alliance Global Partners analyst James Molloy initiated coverage on Ampio Ph

Ampio Pharmaceuticals Inc (AMEX:AMPE) shares are trading significantly higher Thursday following bullish analyst coverage. Alliance Global Partners analyst James Molloy initiated coverage on Ampio Ph

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus NuCana Discontinues Biliary Tract Cancer Study Following Futility Analysis NuCana plc (NASDAQ: NCNA) s

Ampio Pharmaceuticals Inc (NYSE: AMPE ) announced data from the modified Intent-to-Treat (mITT) population in the AP-013 Phase 3 trial of Ampion in severe osteoarthritis of the knee (OAK). The AP-013 study was designed to confirm the efficacy observed in the first pivotal trial, AP-003-A, and was powered to detect treatment differences between Ampion and saline control. In the mITT population (n = 618), which retained more than 85% power … Full story available on Benzinga.com

ENGLEWOOD, Colo., March 2, 2022 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunomodulatory therapies for common inflammatory conditions, today announced positive data from the modified Intent-to-Treat…

Baudax Bio, Inc. (NASDAQ:BXRX) with the stream of -2.56% also noticed, India Ampio Pharmaceuticals, Inc. (AMEX:AMPE) encountered a rapid change of 0.03% in the last hour of Thursdays trading session. The post Traders shouldnt Staggering on this: Baudax Bio, Inc. (NASDAQ:BXRX), Ampio Pharmaceuticals, Inc. (AMEX:AMPE) appeared first on Stocks Equity .

Zacks Investment Research lowered shares of Ampio Pharmaceuticals (NYSEAMERICAN:AMPE) from a buy rating to a hold rating in a report issued on Thursday morning, Zacks.com reports. According to Zacks, Ampio Pharmaceuticals, Inc. develops proprietary drugs for metabolic disease, eye disease, kidney disease, inflammation, CNS disease, and male sexual dysfunction. Principal products offered by the Company []